Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > News > Dose-Dense Chemotherapy Plus Bevacizumab Followed by Nab-Paclitaxel Appears Cardiac Safe in Early-Stage Breast Cancer: Presented at SABCS

December 16th, 2008

Dose-Dense Chemotherapy Plus Bevacizumab Followed by Nab-Paclitaxel Appears Cardiac Safe in Early-Stage Breast Cancer: Presented at SABCS

Abstract:
A dose-dense anthracycline-based therapy that includes bevacizumab followed by nanoparticle albumin-bound paclitaxel (nab-paclitaxel) appears to avoid serious cardiac toxicity in its role as adjuvant treatment for early-stage breast cancer, researchers reported at the 31st Annual San Antonio Breast Cancer Symposium (SABCS).

Heather McArthur, MD, Memorial Sloan-Kettering Cancer Center, New York, New York and colleagues enrolled 80 women with early-stage breast cancer into a trial in which patients were treated with bevacizumab 10 mg/kg administered intravenously every 2 weeks for 8 cycles, concurrently with doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles, and then nab-paclitaxel 260 mg/m2 every 2 weeks for 4 cycles. After 8 cycles, for the rest of 1 year, bevacizumab was administered at a dose of 15 mg/kg every 3 weeks. Pegfilgrastim was administered on day 2 of each chemotherapy cycle.

Source:
docguide.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

'Microcombing' creates stronger, more conductive carbon nanotube films May 5th, 2015

Testing Facility for Graphene Enhanced Composite Pipes May 5th, 2015

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT May 5th, 2015

Silicon Storage Technology and GLOBALFOUNDRIES Announce Qualification of Automotive Grade 55nm Embedded Flash Memory Technology May 5th, 2015

Nanomedicine

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT May 5th, 2015

Arrowhead to Report Fiscal 2015 Second Quarter Financial Results May 4th, 2015

New Nanodrug Produced in Iran from Milk Thistle May 4th, 2015

Antibacterial Ceramic Nanoparticles, Appropriate Material for Medical Devices May 3rd, 2015

Announcements

'Microcombing' creates stronger, more conductive carbon nanotube films May 5th, 2015

Testing Facility for Graphene Enhanced Composite Pipes May 5th, 2015

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT May 5th, 2015

Silicon Storage Technology and GLOBALFOUNDRIES Announce Qualification of Automotive Grade 55nm Embedded Flash Memory Technology May 5th, 2015

Events/Classes

Oxford Instruments Asylum Research in Conjunction with the MRS OnDemand® Webinar Series Presents: “Beyond Topography: New Advances in AFM Characterization of Polymers” May 28, 2015 May 5th, 2015

Arrowhead to Report Fiscal 2015 Second Quarter Financial Results May 4th, 2015

Nanometrics to Present at the B. Riley & Co. 16th Annual Investor Conference May 2nd, 2015

No Hogwarts invitation required: Invisibility cloaks move into the real-life classroom: A new solid-state device can demonstrate the physical principles of invisibility cloaks without special equipment or magic spells April 30th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project